Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

-- Teprotumumab is marketed under the brand name TEPEZZA in the United States -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical

Related Keywords

Japan ,United States ,Ireland ,Kurume ,Fukuoka ,Japanese ,Ruth Venning ,Tina Ventura ,Yuji Hiromatsu ,Ray Gordon ,Rachel Vann ,Elizabethhz Thompson ,Instagram ,Product Communications ,Linkedin ,Twitter ,Visa ,Drug Administration ,Nasdaq ,European Group On Grave Orbitopathy ,Facebook ,Devices Agency ,Japan Pharmaceuticals ,Kurume Medical Center ,Priority Review ,Orphan Drug ,Fast Track ,Breakthrough Therapy ,Clinical Activity Score ,Grave Ophthalmopathy Quality ,Thyroid Eye Disease ,Medical Devices Agency ,Grave Orbitopathy ,Reduce Proptosis ,Teprotumumab Infusions ,Clinical Study ,Japan Registry ,Clinical Trials ,Thyroid Associated ,Grave Disease Is Mediated Through ,Insulin Like Growth Factor ,Clinical Practice Guidelines ,Medical Management ,European Group ,Vice President ,Investor Relations ,States Media ,Horizon ,Herapeutics ,Nitiates ,Hase ,Linical ,Trial ,Optic ,Valuating ,Teprotumumab ,Treatment ,Ctive ,Thyroid ,Disease ,